Related Experiment Video
Updated: Feb 6, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Long Noncoding RNA EGFR-AS1 Promotes Cell Proliferation by Increasing EGFR mRNA Stability in Gastric Cancer
Jiaojiao Hu1, Yingying Qian2, Lipan Peng3
1Nanjing Maternity and Child Health Care Institute, Nanjing Maternity and Child Health Care Hospital, Obsterics and Gynecology Hospital Affiliated to Nanjing Medical University, Nanjing, China.
Background/Aims:
LncRNA EGFR-AS1 is an antisense transcript of EGFR, which plays a key role in gastric cancer progression. This study was aimed to explore the effects of lncRNA EGFR-AS1 on GC and the underling mechanisms.
Methods:
The silencing of EGFR-AS1 expression was performed by using EGFR-AS1 shRNA lentivirus in MGC803 and SGC-7901 GC cell. The levels of lncRNA EGFR-AS1 and EGFR were detected by qPCR and western blot. Cell proliferation was assessed by CCK-8, EdU, and colony formation assays. The EGFR mRNA stability was explored by using RNA synthesis inhibitor α-amanitin.
Results:
In our study, EGFR-AS1 significantly up-regulated in GC tissues and correlated with tumor size. And the expression of EGFR-AS1 positively correlated with EGFR in tissues. Moreover, knock-down of EGFR-AS1 inhibited the proliferation of GC cells via suppressing EGFR-dependent PI3K/AKT pathway in vitro and in vivo. Mechanismly, depletion of EGFR-AS1 was found to decrease EGFR expression by reduction of EGFR mRNA stability.
Conclusion:
Our findings suggested that EGFR-AS1 might have an oncogenic effect on GC and serve as a potential target of GC.
Insights
Long non-coding RNA EGFR-AS1 promotes gastric cancer (GC) progression by increasing EGFR expression and stabilizing its mRNA. Silencing EGFR-AS1 inhibits GC cell proliferation, suggesting it as a potential GC therapeutic target.
Area of Science:
- Molecular Biology
- Oncology
- Gene Expression Regulation
Background:
- Gastric cancer (GC) is a significant health concern.
- Long non-coding RNA (lncRNA) EGFR-AS1 is implicated in GC progression.
- EGFR-AS1 acts as an antisense transcript to the Epidermal Growth Factor Receptor (EGFR).
Purpose of the Study:
- To investigate the role of lncRNA EGFR-AS1 in gastric cancer.
- To elucidate the underlying mechanisms by which EGFR-AS1 influences GC.
- To assess EGFR-AS1 as a potential therapeutic target for GC.
Main Methods:
- Silencing EGFR-AS1 expression using shRNA lentivirus in GC cell lines (MGC803, SGC-7901).
- Quantification of lncRNA EGFR-AS1 and EGFR mRNA/protein levels via qPCR and Western Blot.
- Assessment of cell proliferation using CCK-8, EdU, and colony formation assays.
- Investigation of EGFR mRNA stability using the RNA synthesis inhibitor α-amanitin.
Main Results:
- EGFR-AS1 was significantly upregulated in GC tissues and correlated with tumor size.
- EGFR-AS1 expression positively correlated with EGFR expression in GC tissues.
- Knockdown of EGFR-AS1 inhibited GC cell proliferation in vitro and in vivo.
- EGFR-AS1 depletion reduced EGFR expression by decreasing EGFR mRNA stability, impacting the PI3K/AKT pathway.
Conclusions:
- lncRNA EGFR-AS1 exhibits oncogenic properties in gastric cancer.
- EGFR-AS1 may promote GC progression through EGFR-dependent pathways.
- EGFR-AS1 represents a potential therapeutic target for gastric cancer treatment.
Related Concept Videos
RNA Stability
mRNA Stability and Gene Expression
Cis-acting Elements involved in mRNA stability
mRNA Stability and Gene Expression
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
The Eukaryotic Promoter Region
Nuclear Export of mRNA

